{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T17:39:15Z","timestamp":1774028355298,"version":"3.50.1"},"reference-count":26,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2018,2,18]],"date-time":"2018-02-18T00:00:00Z","timestamp":1518912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Urology"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p> Treatment options for refractory recurrent urinary tract infections (UTI) are limited; therefore, we sought to determine if intravesical instillations with heparin effectively treat recurrent UTIs. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p> Patients at an academic medical center who received intravesical instillations with heparin for recurrent UTIs\/chronic cystitis between January 2011 and December 2015 were identified via International Classification of Diseases, Ninth Revision (ICD-9) and Current Procedural Terminology (CPT) procedure codes. All cases were analyzed for frequency of UTIs during the treatment phase as well as for the subsequent 6 months after completion of therapy. Demographic, clinical and treatment related factors were then collected from the medical records to draw associations with success or failure of treatment. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p> Thirty-nine women were treated with heparin intravesical instillations for recurrent UTIs. The average age of the cohort was 68.38 years [range 25\u201388, standard deviation (SD) 12.92], with mean parity 2.38 (range 0\u20137, SD 1.55) and mean body mass index 27.85 (range 19.5\u201337.9, SD 4.84). A total of 84.6% completed the recommended 6-week treatment course while 69.2% went on to an additional maintenance phase. Twelve patients (30.8%) had a culture-proven UTI during the treatment phase. In the 6-month follow-up period, 46.2% of patients had at least one UTI with only seven patients (17.9%) meeting criteria for recurrent UTIs (two or more UTIs in 6 months). On univariable assessment, development of recurrent UTIs after completion of instillation therapy was associated with increasing age and vaginal estrogen use during the instillation treatment course. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p> Intravesical instillation with heparin is an effective option to consider for the treatment of refractory recurrent UTIs. <\/jats:p><\/jats:sec>","DOI":"10.1177\/1756287218757655","type":"journal-article","created":{"date-parts":[[2018,2,19]],"date-time":"2018-02-19T07:04:00Z","timestamp":1519023840000},"page":"157-163","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Intravesical instillations for the treatment of refractory recurrent urinary tract infections"],"prefix":"10.1177","volume":"10","author":[{"given":"Sonia","family":"Dutta","sequence":"first","affiliation":[{"name":"Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, University of California, Irvine Medical Center, 333 City Blvd, West, Suite 1400, Orange, CA 92868, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicia","family":"Lane","sequence":"additional","affiliation":[{"name":"University of California, Irvine Medical Center, Orange, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,2,18]]},"reference":[{"key":"bibr1-1756287218757655","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000155596.98780.82"},{"key":"bibr2-1756287218757655","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.80.3.331"},{"key":"bibr3-1756287218757655","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-014-2569-5"},{"key":"bibr4-1756287218757655","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1104429"},{"key":"bibr5-1756287218757655","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.03.020"},{"key":"bibr6-1756287218757655","doi-asserted-by":"publisher","DOI":"10.1111\/iju.12430"},{"key":"bibr7-1756287218757655","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgo.2006.11.025"},{"key":"bibr8-1756287218757655","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2004.04850.x"},{"key":"bibr9-1756287218757655","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-012-1794-z"},{"key":"bibr10-1756287218757655","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.12.039"},{"key":"bibr11-1756287218757655","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.1989"},{"key":"bibr12-1756287218757655","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1994.tb07634.x"},{"key":"bibr13-1756287218757655","doi-asserted-by":"publisher","DOI":"10.1007\/BF00182044"},{"key":"bibr14-1756287218757655","doi-asserted-by":"publisher","DOI":"10.1016\/S1078-1439(00)00074-0"},{"key":"bibr15-1756287218757655","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00180-5"},{"key":"bibr16-1756287218757655","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.03.064"},{"key":"bibr17-1756287218757655","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)01130-X"},{"key":"bibr18-1756287218757655","doi-asserted-by":"publisher","DOI":"10.1007\/s003450050168"},{"key":"bibr19-1756287218757655","doi-asserted-by":"publisher","DOI":"10.1159\/000345047"},{"key":"bibr20-1756287218757655","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-012-1957-y"},{"key":"bibr21-1756287218757655","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009669"},{"key":"bibr22-1756287218757655","doi-asserted-by":"publisher","DOI":"10.1177\/1756287213504804"},{"key":"bibr23-1756287218757655","doi-asserted-by":"publisher","DOI":"10.1016\/j.urols.2013.11.007"},{"key":"bibr24-1756287218757655","doi-asserted-by":"publisher","DOI":"10.1086\/313596"},{"key":"bibr25-1756287218757655","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2004.06.014"},{"key":"bibr26-1756287218757655","doi-asserted-by":"publisher","DOI":"10.1097\/SPV.0b013e31824b76bd"}],"container-title":["Therapeutic Advances in Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756287218757655","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1756287218757655","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756287218757655","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T09:52:59Z","timestamp":1740822779000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1756287218757655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,18]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1177\/1756287218757655"],"URL":"https:\/\/doi.org\/10.1177\/1756287218757655","relation":{},"ISSN":["1756-2872","1756-2880"],"issn-type":[{"value":"1756-2872","type":"print"},{"value":"1756-2880","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,18]]}}}